Trial Profile
Safety and Efficacy Study of Pl-vegf165 to Treat Secondary Raynaud's Phenomenon Caused by Systemic Scleroderma
Status:
Not yet recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 20 Jan 2020
Price :
$35
*
At a glance
- Drugs Vascular endothelial growth factor-165 gene therapy (Neovasculgen) (Primary)
- Indications Raynaud's disease
- Focus Adverse reactions; Therapeutic Use
- Sponsors Human Stem Cells Institute
- 10 Feb 2015 New trial record